Focused On-demand Library for Nuclear pore complex protein Nup133

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8WUM0

UPID:

NU133_HUMAN

Alternative names:

133 kDa nucleoporin; Nucleoporin Nup133

Alternative UPACC:

Q8WUM0; B2RAZ8; Q5T8N0; Q9H9W2; Q9NV71; Q9NVC4

Background:

The Nuclear pore complex protein Nup133, also known as a 133 kDa nucleoporin, plays a crucial role in poly(A)+ RNA transport and nephrogenesis. This protein is a key component of the nuclear pore complex, facilitating the transport of molecules between the nucleus and the cytoplasm.

Therapeutic significance:

Nup133's involvement in diseases such as Nephrotic syndrome 18 and Galloway-Mowat syndrome 8, both of which have significant renal and neurological implications, underscores its potential as a target for therapeutic intervention. Understanding the role of Nuclear pore complex protein Nup133 could open doors to potential therapeutic strategies.